OREXIGEN THERAPEUTICS INC's ticker is OREXXXXX and the CUSIP is 686164104. A total of 124 filers reported holding OREXIGEN THERAPEUTICS INC in Q4 2013. The put-call ratio across all filers is 0.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $532,000 | -49.0% | 1,239,113 | -33.3% | 0.00% | -100.0% |
| Q1 2016 | $1,044,000 | -63.6% | 1,858,425 | +11.3% | 0.00% | -50.0% |
| Q4 2015 | $2,870,000 | -52.8% | 1,669,441 | -42.1% | 0.00% | -60.0% |
| Q3 2015 | $6,082,000 | -57.2% | 2,882,824 | +0.5% | 0.01% | -44.4% |
| Q2 2015 | $14,200,000 | -30.9% | 2,869,069 | +9.3% | 0.01% | -30.8% |
| Q1 2015 | $20,549,000 | +33.0% | 2,624,658 | +3.0% | 0.01% | +30.0% |
| Q4 2014 | $15,445,000 | +70.8% | 2,548,737 | +20.1% | 0.01% | +66.7% |
| Q3 2014 | $9,041,000 | -17.0% | 2,122,553 | +20.4% | 0.01% | -14.3% |
| Q2 2014 | $10,895,000 | -6.4% | 1,763,071 | -1.5% | 0.01% | -12.5% |
| Q1 2014 | $11,637,000 | -7.9% | 1,790,586 | -20.2% | 0.01% | -11.1% |
| Q4 2013 | $12,634,000 | -23.1% | 2,244,312 | -16.2% | 0.01% | -25.0% |
| Q3 2013 | $16,420,000 | – | 2,678,652 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 1,900,000 | $11,106,000 | 1.50% |
| Redmile Group, LLC | 1,190,440 | $6,958,000 | 1.23% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 613,560 | $3,586,000 | 0.63% |
| Montibus Capital Management LLC | 818,575 | $4,784,570,000 | 0.60% |
| KOPP INVESTMENT ADVISORS LLC | 213,752 | $1,249,000 | 0.49% |
| PFM Health Sciences, LP | 3,646,260 | $21,312,000 | 0.44% |
| APEX CAPITAL, LLC | 1,092,900 | $6,388,000 | 0.44% |
| FIRST MANHATTAN CO. LLC. | 6,141,636 | $46,860,000 | 0.32% |
| JHL Capital Group LLC | 300,000 | $1,755,000 | 0.27% |
| Partner Investment Management, L.P. | 188,732 | $1,103,000 | 0.25% |